Scarica l'app Stockscreener
1.18
0.85%
0.01
Dopo l'orario di chiusura:
1.19
0.01
+0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.17
Aprire:
$1.15
Volume 24 ore:
1.20M
Relative Volume:
0.60
Capitalizzazione di mercato:
$428.81M
Reddito:
$1.21M
Utile/perdita netta:
$-177.12M
Rapporto P/E:
-1.475
EPS:
-0.8
Flusso di cassa netto:
$-162.37M
1 W Prestazione:
+2.61%
1M Prestazione:
-15.11%
6M Prestazione:
+28.74%
1 anno Prestazione:
+37.29%
Intervallo 1D:
$1.14
$1.21
Intervallo di 1 settimana:
$1.11
$1.23
Portata 52W:
$0.2836
$1.66
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Nome
Lexicon Pharmaceuticals Inc
Settore
Industria
Telefono
(281) 863-3000
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Confronta LXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.18 | 425.18M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-30 | Iniziato | Leerink Partners | Outperform |
| 2023-03-07 | Iniziato | Jefferies | Hold |
| 2022-08-12 | Iniziato | Piper Sandler | Overweight |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-18 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Downgrade | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Downgrade | Stifel | Buy → Hold |
| 2019-03-25 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Reiterato | Stifel | Buy |
| 2018-02-23 | Downgrade | Needham | Buy → Hold |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-01 | Reiterato | Wedbush | Outperform |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-05 | Reiterato | Wedbush | Outperform |
| 2016-08-02 | Iniziato | Citigroup | Buy |
| 2016-03-02 | Reiterato | Wedbush | Outperform |
| 2015-11-09 | Reiterato | Wedbush | Outperform |
| 2015-09-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Downgrade | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Making Medical Innovation Matter To Patients With Simplified Trial Design - Clinical Leader
Will Lexicon Pharmaceuticals Inc. stock maintain growth storyAnalyst Downgrade & Fast Gain Stock Tips - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock cheap at current valuationTrade Performance Summary & Growth-Oriented Investment Plans - ulpravda.ru
Market Rankings: Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Performance Recap & Scalable Portfolio Growth Ideas - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock resilient to inflationJuly 2025 PostEarnings & Real-Time Buy Signal Notifications - ulpravda.ru
Can Lexicon Pharmaceuticals Inc. stock continue upward trendTake Profit Strategies & Outstanding Growth Stocks - ulpravda.ru
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastInstitutional Buying Trends & Calculate Profit Targets With AI Accuracy - earlytimes.in
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies - Traders Union
How currency fluctuations impact Lexicon Pharmaceuticals Inc. stockWeekly Profit Summary & Stock Portfolio Risk Control - Улправда
Patterns Watch: Will Lexicon Pharmaceuticals Inc. stock outperform Dow Jones index2025 Fundamental Recap & Smart Allocation Stock Reports - moha.gov.vn
Investment Report: Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekers2025 Buyback Activity & Risk Managed Trade Strategies - Улправда
AI Stocks: Can Lexicon Pharmaceuticals Inc. stock beat market expectations this quarterVolume Spike & Real-Time Stock Movement Alerts - Улправда
Why Lexicon Pharmaceuticals Inc. stock is a must watch in 2025July 2025 Patterns & Entry Point Strategy Guides - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock weather global recessionMarket Sentiment Report & Comprehensive Market Scan Reports - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock rebound after recent weaknessWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - DonanımHaber
How Lexicon Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Final Week & AI Optimized Trade Strategies - DonanımHaber
Surprises Report: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsEarnings Growth Report & Daily Oversold Stock Bounce Ideas - Улправда
Is Lexicon Pharmaceuticals Inc. stock in correction or buying zone2025 Key Highlights & Real-Time Price Movement Reports - Улправда
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money - simplywall.st
Short Covering: How risky is Lexicon Pharmaceuticals Inc stock now2025 Fundamental Recap & Community Verified Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data - Traders Union
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon publishes preclinical data supporting LX9851 obesity treatment - StreetInsider
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 - Yahoo Finance
Daily News - FinancialContent
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - The Manila Times
Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients - TradingView
Lexicon Pharmaceuticals to Present Clinical Data on Sotagliflozin at CVCT 2025 Conference - Quiver Quantitative
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development - MSN
Is Lexicon Pharmaceuticals Inc. stock attractive for ETFs2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Year in Review: Local co. striking deal worth up to $1B with Ozempic maker was a Deal of the Week - The Business Journals
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha
Piper Sandler Healthcare Conference - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):